PRODUCTS

products are part of our comprehensive inventory

COMPANY

employees turning possibilities into reality for people and patients

Explore our diverse pharmaceutical solutions.

Cleomycin™ 300 Capsule: Each capsule contains Clindamycin Hydrochloride USP equivalent to Clindamycin 300 mg.

Composition

Clindamycin has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram-positive bacteria such as streptococci, staphylococci, and pneumococci:<ul><li>Upper respiratory tract infections</li><li>Lower respiratory tract infections</li><li>Skin and soft tissue infections</li><li>Bone and joint infections</li><li>Pelvic infections</li><li>Intra-abdominal infections</li><li>Septicemia and endocarditis</li><li>Dental infections</li><li>As an alternative therapy when used in combination with quinine or amodiaquine for the treatment of multi-drug resistant Plasmodium falciparum infection.</li></ul>

Indication

Adults: Serious Infections: 150 mg - 300 mg every six hours.More severe infections: 300 mg - 450 mg every six hours.To avoid the possibility of esophageal irritation, Clindamycin capsules should be taken with a full glass of water.

Dosage & Administration

Medications used to combat bacterial infections and inhibit the growth of bacteria.

Anti-infectives

Lindex DS, classified within the anti-infectives therapeutic class, is an antibiotic medication formulated as a powder for oral suspension. Each 5 ml of the reconstituted suspension contains 250 mg of Cephradine, a first-generation cephalosporin antibiotic. This medication is effective against a variety of bacteria and is typically used in treating bacterial infections. The product, when reconstituted, provides a total volume of 100 ml of suspension.

Lindex DS (Cephradine 250 mg per 5 ml) is indicated for the treatment of various bacterial infections. These infections may include respiratory tract infections (such as bronchitis and pneumonia), ear infections (like otitis media), skin and soft tissue infections, and urinary tract infections. Cephradine works by interfering with the formation of the bacterial cell wall, leading to the death of the bacteria. It's effective against a range of bacteria, making it a suitable choice for various infections.

The dosage of Lindex DS is typically determined based on the patient's age, weight, the severity of the infection, and the type of infecting organism. For children and adults, the dosing regimen is usually calculated as per body weight, with a common dosage being 25-50 mg/kg of body weight per day, divided into multiple doses. To prepare the suspension, the powder should be reconstituted with water according to the instructions provided, ensuring the total volume reaches 100 ml. The suspension should be shaken well before each use to ensure the medication is properly mixed. It's important to complete the full course of the antibiotic as prescribed, even if symptoms improve before the end of the treatment, to fully eradicate the infection and prevent the development of antibiotic resistance. As the label warns, "Do not use without prescription of registered physician," it's crucial for patients to consult a healthcare provider before starting treatment with Lindex DS. Any adjustments to the dosage or duration of treatment should be made only under medical supervision. Patients or caregivers should also be informed about the proper storage of the suspension and the disposal of any unused portion after the course of treatment is completed.

Maxbac 250mg IV/IM Injecti, classified under the anti-infectives therapeutic class, is a formulation of Ceftazidime, an antibiotic belonging to the cephalosporin class. Each vial of Maxbac 250mg IV/IM Injecti 10 contains 250 mg of Ceftazidime USP (as Pentahydrate), accompanied by Sodium Carbonate as a buffer. The medication is provided in a form that requires reconstitution, and for this purpose, each package includes an ampoule containing 5 ml of water for injection. Additionally, Maxbac 250mg IV/IM Injecti is supplied with a sterile disposable syringe, an alcohol prep pad, and a strip bandage, facilitating safe and sterile administration.

Ceftazidime, the active ingredient in Maxbac 250mg IV/IM Injecti, is indicated for the treatment of a variety of bacterial infections. This antibiotic is particularly effective against Gram-negative bacteria and is used in the treatment of severe or life-threatening infections like pneumonia, urinary tract infections, skin infections, intra-abdominal infections, and infections in immunocompromised patients. Ceftazidime is also commonly used in hospital settings for managing infections in patients with limited treatment options due to antibiotic resistance.

The dosage of Maxbac 250mg IV/IM Injecti (Ceftazidime) varies depending on the type, severity, and site of infection, as well as the patient's age, weight, and renal function. The reconstituted solution is administered intravenously or intramuscularly. For adult patients, the typical dose ranges but should always be determined by a healthcare professional based on specific patient needs. The administration of Maxbac 250mg IV/IM Injecti involves reconstituting the Ceftazidime powder in the vial with the provided sterile water for injection. The solution should be prepared using aseptic techniques, utilizing the alcohol prep pad for cleaning and the sterile syringe for administration. After reconstitution, the solution must be used within a specified period to maintain its efficacy and reduce the risk of contamination. Patients and caregivers should be instructed in proper preparation and administration techniques, and the use of the strip bandage for post-injection care. It is essential to complete the full course of therapy as prescribed, even if symptoms improve, to ensure the effective treatment of the infection and reduce the risk of developing antibiotic resistance. Any adjustments in dosage or treatment regimen should be made under the guidance of a healthcare provider.

Maxbac 500mg is an antibiotic medication categorized under the anti-infectives therapeutic class, specifically formulated for intravenous (IV) or intramuscular (IM) administration. Each vial of Maxbac contains 500 mg of Ceftazidime USP (as Pentahydrate), a broad-spectrum cephalosporin antibiotic. The formulation also includes Sodium Carbonate as a buffer. To facilitate reconstitution of the powder, each package of Maxbac 500mg is accompanied by an ampoule containing 5 ml of water for injection. The product is also supplied with a sterile disposable syringe, an alcohol prep pad, and a strip bandage to ensure a safe and sterile administration process.

Ceftazidime, the active ingredient in Maxbac 500mg, is indicated for the treatment of various bacterial infections. It is particularly effective against Gram-negative bacteria and is frequently used in hospital settings for severe or resistant infections. Indications for Ceftazidime include pneumonia, urinary tract infections, skin infections, intra-abdominal infections, and infections in immunocompromised patients. It is also used for infections in patients who have few other antibiotic options due to resistance issues.

The dosage of Maxbac 500mg (Ceftazidime) should be determined by a healthcare professional and varies based on the type, severity, and location of the infection, as well as patient-specific factors such as age, weight, and kidney function. The medication can be administered either intravenously or intramuscularly. For the preparation of the injection, the Ceftazidime powder in the vial is reconstituted with the provided 5 ml of sterile water. It's crucial to adhere to aseptic techniques during preparation, using the alcohol prep pad for sterilization and the sterile syringe for drawing and administering the solution. Once reconstituted, the solution should be used within a specified timeframe to ensure efficacy and prevent contamination. Proper administration techniques are important, and patients or caregivers should be trained in these methods. The included strip bandage can be used for post-injection wound care. Patients are advised to complete the full prescribed course of Maxbac 500mg, even if symptoms improve early, to ensure complete eradication of the infection and to reduce the risk of antibiotic resistance. Dosage adjustments, if necessary, should always be guided by a healthcare provider.

Ngcef® 200 Capsule: Each capsule contains Cefixime Trihydrate BP equivalent to Cefixime 200 mg. Ngcef® 400 Capsule: Each capsule contains Cefixime Trihydrate BP equivalent to Cefixime 400 mg. Ngcef® Granules for Suspension: When reconstituted each 5 ml of suspension contains Cefixime Trihydrate BP equivalent to Cefixime 100 mg. Ngcef® DS Granules for Suspension: When reconstituted each 5 ml of suspension contains Cefixime Trihydrate BP equivalent to Cefixime 200 mg.

Cefixime is indicated in the treatment of the following infections caused by susceptible strains of the microorganisms: Pharyngitis, Tonsillitis, Otitis media, Acute bronchitis, Acute Exacerbations of Chronic Bronchitis, Urinary Tract Infection and Uncomplicated Gonorrhea.

Capsule: 1 or 2 capsule as a single dose or in two divided doses daily for 7 to 14 days, according to the severity of infection. Suspension: 8 mg / kg daily as a single dose or in two divided doses daily for 7 to 14 days, according to the severity of infection or for children of age ½ - 1 year : 3.75 ml or 75 mg, 1 - 4 years : 5 ml or 100 mg, 5 - 10 years : 10 ml or 200 mg, 11 - 12 years : 15 ml or 300 mg and above 12 years : adult dose.

Ngcef® 200 Capsule: Each capsule contains Cefixime Trihydrate BP equivalent to Cefixime 200 mg. Ngcef® 400 Capsule: Each capsule contains Cefixime Trihydrate BP equivalent to Cefixime 400 mg. Ngcef® Granules for Suspension: When reconstituted each 5 ml of suspension contains Cefixime Trihydrate BP equivalent to Cefixime 100 mg. Ngcef® DS Granules for Suspension: When reconstituted each 5 ml of suspension contains Cefixime Trihydrate BP equivalent to Cefixime 200 mg.

Oryx® 250 mg IM/IV Injection: Each vial contains dry substance equivalent to 250 mg Ceftriaxone (as sterile Ceftriaxone Sodium USP) accompanied by a solvent ampoule of 2 ml Lidocaine HCI USP 1% Injection for IM injection or 5 ml Water for Injection USP for IV injection. Oryx® 500 mg IM/IV Injection: Each vial contains dry substance equivalent to 500 mg Ceftriaxone (as sterile Ceftriaxone Sodium USP) accompanied by a solvent ampoule of 2 ml Lidocaine HCI USP 1% Injection for IM injection or 5 ml Water for Injection USP for IV injection. Oryx® 1 g IM/IV Injection: Each vial contains dry substance equivalent to 1 g Ceftriaxone (as sterile Ceftriaxone Sodium USP) accompanied by a solvent ampoule of 3.5 ml Lidocaine HCI USP 1% Injection for IM injection or 10 ml Water for Injection USP for IV injection. Oryx® 2 g IV Injection: Each vial contains dry substance equivalent to 2 g Ceftriaxone (as sterile Ceftriaxone Sodium USP) and each of two ampoules contains 10 ml Water for Injection USP for IV injection.

Oryx® is indicated for the treatment of the following infections when caused by susceptible organisms: Lower respiratory tract infections, Acute bacterial otitis media, Skin and skin-structure infections, Urinary tract infections (complicated and uncomplicated), Uncomplicated gonorrhea (cervical/urethral and rectal), Pelvic inflammatory disease, Bacterial septicemia, Bone and joint infections, Intra-abdominal infections, Meningitis and in Surgical prophylaxis.

Oryx® can be administered either intravenously or intramuscularly. Dosage and mode of administration should be determined by severity of infection, susceptibility of causative organisms and the patient's condition. Under most circumstances, once-daily dose or in the specified indications, a single dose will give satisfactory therapeutic results. Adults and children over 12 years: The usual dosage is 1-2 g of Oryx® once daily (every 24 hours). In severe cases or in infections caused by moderately sensitive organisms, the dosage may be raised to 4 g once daily. Neonates, infants and children up to 12 years: The following dosage schedules are recommended for once daily administration. Neonates (up to 14 days): A daily dose of 20-50 mg/kg bodyweight, not to exceed 50 mg/kg, on account of the immaturity of the infant's enzyme systems. It is not necessary to differentiate between premature and term infants. Infants and children (15 days to 12 years): A daily dose of 20-80 mg/kg. For children with bodyweights of 50 kg or more, the usual adult dosage should be used. Intravenous doses of &gt; 50 mg/kg body weight should be given by infusion over at least 30 minutes. Elderly patients: The dosages recommended for adults require no modification in case of geriatric patients. Duration of therapy: Oryx® therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required. When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days. Combination therapy: Synergy between Ceftriaxone and aminoglycosides has been demonstrated with many gram-negative bacilli under experimental conditions. Although enhanced activity of such combinations is not always predictable, it should be considered in severe and life threatening infections due to microorganisms such as Pseudomonas aeruginosa. Because of physical incompatibility, the two drugs must be administered separately at the recommended dosages. Meningitis: In bacterial meningitis in infants and children, treatment begins with doses of 100 mg/kg (not to exceed 4 g) once daily. As soon as the causative organism has been identified and its sensitivity determined, the dosage can be reduced accordingly. Best results have been found with the following duration of therapy: Neisseria meningitidis-4 days, Haemophilus influenzae-6 days, Streptococcus pneumoniae-7 days, Susceptible Enterobacteriaceae-10 to 14 days. Gonorrhoea (penicillinase - producing and nonpenicillinase - producing strains): a single IM dose of 250 mg Oryx® is recommended. Perioperative prophylaxis: A single dose of 1-2 g depending on the risk of infection of 30-90 minutes prior to surgery. In colorectal surgery, administration of Oryx® with or without a 5-nitroimidazole, e.g. Ornidazole, has been proven effective. Impaired renal and hepatic function: In patients with impaired renal function, there is no need to reduce the dosage of Oryx® provided hepatic function is intact. Only in cases of preterminal renal failure (creatinine clearance &lt;10 ml/min) should the Oryx® dosage not exceed 2 g daily. In patients with liver damage, there is no need for the dosage to be reduced provided renal function is intact. In patients with both severe renal and hepatic dysfunction, the plasma concentrations of Ceftriaxone should be determined at regular intervals and, if necessary, the dose should be adjusted. In patients undergoing dialysis, no additional supplementary dosing is required following the dialysis. Plasma concentrations should, however, be monitored, to determine whether dosage adjustments are necessary, since the elimination rate in these patients may be altered.

Perpen® 250: Each capsule contains Flucloxacillin 250 mg as Flucloxacillin Sodium BP. Perpen® 500: Each capsule contains Flucloxacillin 500 mg as Flucloxacillin Sodium BP. Perpen® Granules for Suspension: When reconstituted, each 5 ml contains Flucloxacillin BP 125mg/5ml as Flucloxacillin Sodium BP.

Perpen® is indicated for the treatment of infections due to Gram-positive organisms, including infections caused by ß-lactamase producing staphylococci. Typical indications include: Skin and Soft Tissue Infections: Boils, abscesses, carbuncles, furunculosis, cellulitis, infected wounds, infected burns, protection of skin grafts, and impetigo. Infected Skin Conditions: Ulcer, eczema and acne etc. Respiratory Tract Infections: Pneumonia, lung abscess, empyema, sinusitis, pharyngitis, tonsillitis, quinsy, otitis media and externa. Other infections caused by Flucloxacillin-sensitive organisms such as osteomyelitis, enteritis, endocarditis, urinary tract infections, meningitis, and septicaemia.

Adult: The usual adult dose is 250mg 6 hourly. In severe infections, the dose may be doubled to 500mg 6 hourly. Children 2-10 years: Half of the adult dose. Children Under 2 Years: Quarter of the adult dose. Osteomyelitis, endocarditis: Up to 8 gm daily, in divided doses six to eight hourly. Doses should be administered half to one hour before meals.

RANFLOX® 500 Tablet: Each film coated tablet contains Ciprofloxacin Hydrochloride BP equivalent to 500 mg Ciprofloxacin. RANFLOX® 750 Tablet: Each film coated tablet contains Ciprofloxacin Hydrochloride BP equivalent to 750 mg Ciprofloxacin.

Ciprofloxacin is indicated for the treatment of single infection or mixed infections caused by two or more susceptible organisms. Ciprofloxacin can also be used for infections caused by organisms resistant to other antibiotics including aminoglycosides, penicillins and cephalosporins. The extensive tissue penetration of Ciprofloxacin combined with its enhanced antibacterial activity (including antipseudomonal activity), enables Ciprofloxacin to be used alone (depending on sensitivity results) or in combination with an aminoglycoside or with beta-lactam antibiotics, for instance, when severe neutropenia is present or with an antibiotic active against anaerobes where the presence of Bacteroides fragilis is suspected. Ciprofloxacin is indicated for the treatment of the following infections caused by sensitive bacteria: Severe systemic infections: Septicaemia, bacteremia, peritonitis, and infections in immunosuppressed patients with hematological or solid tumors and in patients in intensive care with specific problems such as infected burns. Respiratory tract infections: Lobar and bronchopneumonia, acute, and chronic bronchitis, acute exacerbation of cystic fibrosis, bronchiectasis, empyema. Urinary tract infections: Uncomplicated and complicated urethritis, cystitis, pyelonephritis, prostatitis, epididymitis. Skin and soft tissue infections: Infected ulcers, wound infections, abscesses, cellulitis, otitis externa, erysipelas, and infected burns. Gastro-intestinal infections: Enteric fever, infective diarrhoea. Infections of the biliary tract: Cholangitis, cholecystitis, empyema of the gall bladder. Intra-abdominal infections: Peritonitis, intra-abdominal abscesses. Bone and joint infections: Osteomyelitis, septic arthritis. Pelvic infections: Salpingitis, endometritis, and pelvic inflammatory diseases. Eye, ear, nose and throat infections: Otitis media, sinusitis, mastoiditis, and tonsillitis. Gonorrhoea : Urethral, rectal and pharyngeal gonorrhoea caused by beta-lactamase producing organisms or organisms moderately sensitive to penicillins.

General dosage recommendations: The dosage of Ciprofloxacinis determined by the sensitivity of the causative organism(s) and the age, weight and renal function of the patient. Adults: The dosage range for adults is 250-750 mg twice daily.

RANZITH® 250 Capsule : Each capsule contains Azithromycin USP250 mg as Azithromycin Dihydrate. RANZITH® 500 Tablet : Each film-coated tablet contains Azithromycin USP500 mg as Azithromycin Dihydrate.

RANZITH® (Azithromycin) is indicated for infections (caused by susceptible organisms) in lower respiratory tract infections including bronchitis and pneumonia, skin and soft tissue infections, otitis media and in upper respiratory tract infections including sinusitis and pharyngitis / tonsillitis, in otitis media and in skin and soft tissue infection. In sexually transmitted disease in men and women RANZITH® (Azithromycin) is indicated in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

Adult: RANZITH® (Azithromycin) should be given as 500 mg once daily orally for 3 days or as an alternative, given over 5 days with 500 mg on day 1, then 250 mg on days 2-5. For sexually transmitted disease caused by Chlamydia trachomatis in adult, the dose is 1 gm given as a single dose. Elderly patients: Normal adult dose is recommended. Children: Children over 6 months 10 mg/kg once daily for 3 days; or body weight 15-25 kg, 200 mg once daily for 3 days; or body weight 26-35 kg, 300 mg once daily for 3 days; or body weight 36-45 kg, 400 mg once daily for 3 days; As common with may other antibiotics Azithromycin should be taken at least 1 hour before or 2 hours after meal and antacids.

Ranzith GS falls under the anti-infectives therapeutic class, specifically designed as a pediatric formulation. It contains Azithromycin, an antibiotic belonging to the macrolide class. The generic composition of Ranzith GS is Azithromycin USP 200 mg per 5 ml. This medication is presented as granules, which when reconstituted, make a 15 ml suspension. Azithromycin works by stopping the growth of bacteria, and it is effective against a wide range of bacterial infections.

Ranzith GS (Azithromycin) is indicated for the treatment of various bacterial infections, especially those affecting the respiratory tract, skin, and ears. Common uses include the treatment of pneumonia, bronchitis, sinusitis, tonsillitis, otitis media, and skin infections. It is also used in treating certain sexually transmitted infections. Azithromycin is suitable for patients who may be allergic to penicillin or for infections caused by bacteria resistant to other antibiotics.

The dosage of Ranzith GS is typically based on the child's weight and the severity of the infection. The standard dosing for pediatric patients often involves administering Azithromycin at a dose of 10 mg/kg body weight once a day for three days or as prescribed by a healthcare provider. The granules for suspension should be reconstituted with water according to the instructions on the package to prepare a 15 ml suspension. Once prepared, the suspension should be measured accurately, usually with a provided measuring device, and given orally. It is important to shake the bottle well before each use to ensure the medication is evenly mixed. The course of the antibiotic should be completed as prescribed, even if the child starts to feel better before the end of the treatment period, to ensure the complete eradication of the bacteria and to prevent the development of antibiotic resistance. Parents and caregivers should be instructed on the proper preparation and administration of the suspension. They should also be advised to store the medication as per the guidelines and to discard any unused suspension after the course of treatment is complete. Any adjustments to the dosage or treatment should be made under the guidance of a healthcare provider.

Ranzith GS 30 ml is an antibiotic medication belonging to the anti-infectives therapeutic class. It is formulated with Azithromycin, a macrolide antibiotic, with a concentration of 200 mg of Azithromycin USP per 5 ml of the prepared suspension. The product is supplied as granules which, when reconstituted, yield a 30 ml suspension. Azithromycin is effective in inhibiting the growth of a broad spectrum of bacteria, making it a versatile treatment for various bacterial infections.

Ranzith GS 30 ml is indicated for the treatment of a range of bacterial infections. This includes respiratory tract infections such as pneumonia and bronchitis, skin and soft tissue infections, otitis media (middle ear infection), and some sexually transmitted infections. It is particularly useful in patients who are allergic to penicillin or in cases where other antibiotics are ineffective due to resistance.

The dosage of Ranzith GS 30 ml is primarily determined by the patient's body weight and the type and severity of the infection. The standard pediatric dosage typically involves administering Azithromycin at 10 mg/kg of body weight once daily for three days. For accurate dosing, the suspension should be prepared according to the manufacturer's instructions, ensuring that the granules are completely dissolved in water to make up the 30 ml suspension. The suspension should be well shaken before each dose to ensure uniformity. It is important to use an appropriate measuring device, usually provided with the medication, to ensure the correct dose is administered. The full course of the antibiotic should be completed as prescribed to effectively eradicate the infection and to prevent the development of antibiotic resistance. Parents and caregivers should be guided on the correct preparation, administration, and storage of the suspension. Any unused portion of the suspension should typically be discarded after the treatment course is completed. Dosage adjustments or changes in the treatment regimen should only be made under the guidance of a healthcare professional.

Ranzith GS 50 ml is classified within the anti-infectives therapeutic class and contains Azithromycin, a broad-spectrum macrolide antibiotic. Each 5 ml of the prepared suspension contains 200 mg of Azithromycin USP. The medication is supplied as granules that, when reconstituted with the appropriate amount of water, yield a 50 ml suspension. Azithromycin works by inhibiting bacterial protein synthesis, effectively treating various bacterial infections.

Ranzith GS 50 ml is indicated for the treatment of several bacterial infections. This includes respiratory infections like pneumonia and bronchitis, skin and soft tissue infections, ear infections such as otitis media, and certain sexually transmitted diseases. It is particularly useful for patients who are allergic to penicillin or when other antibiotics are not suitable due to resistance.

The dosage of Ranzith GS 50 ml is typically determined based on the patient's weight and the nature of the infection. In pediatric patients, the common dosing regimen is Azithromycin at 10 mg/kg of body weight once daily for three days. The exact dosage should be prescribed by a healthcare provider. To prepare the suspension, the granules should be reconstituted with water as per the instructions provided. It's important to shake the bottle well before each dose to ensure the medication is evenly dispersed. An appropriate measuring device should be used to administer the correct amount of suspension. Patients should complete the entire prescribed course of Ranzith GS 50 ml, even if symptoms improve early, to ensure full eradication of the infection and to prevent antibiotic resistance. The medication should be stored as directed and any unused suspension should be disposed of after the course of treatment is finished. Dosage adjustments or changes in the treatment regimen should be made only under the guidance of a healthcare professional.

Adult:RANZITH® (Azithromycin) should be given as 500 mg once daily orally for 3 days or as an alternative, given over 5 days with 500 mg on day 1, then 250 mg on days 2-5. For sexually transmitted disease caused by Chlamydia trachomatis in adult, the dose is 1 gm given as a single dose. Elderly patients: Normal adult dose is recommended. ﻿Children: Children over 6 months 10 mg/kg once daily for 3 days; or body weight 15-25 kg, 200 mg once daily for 3 days; or body weight 26-35 kg, 300 mg once daily for 3 days; or body weight 36-45 kg, 400 mg once daily for 3 days; As common with may other antibiotics Azithromycin should be taken at least 1 hour before or 2 hours after meal and antacids.

Recofast 250, belonging to the anti-infectives therapeutic class, is a medication formulated with Cefuroxime, a second-generation cephalosporin antibiotic. Each film-coated tablet of Recofast contains Cefuroxime Axetil USP, which is equivalent to 250 mg of Cefuroxime. Cefuroxime is effective against a broad range of bacteria and is used to treat various bacterial infections. It works by interfering with the formation of the bacteria's cell wall, thus leading to its rupture and death.

Recofast 250 (Cefuroxime 250 mg) is indicated for the treatment of various bacterial infections. These include respiratory tract infections like bronchitis and pneumonia, urinary tract infections, skin and soft tissue infections, and infections of the ear, throat, and sinuses. It is also used in treating Lyme disease and can be prescribed as a prophylactic treatment in certain surgical procedures to prevent postoperative infections.

The dosage of Recofast 250 (Cefuroxime 250 mg) varies depending on the type and severity of the infection, as well as the patient's age and kidney function. For adults and children with normal kidney function, the typical dosage ranges from 250 mg to 500 mg twice daily, taken orally. The tablets should be taken with food to enhance absorption. It is crucial to complete the full course of the antibiotic as prescribed, even if symptoms improve before the medication is finished, to ensure the complete eradication of the bacteria and to prevent the development of antibiotic resistance. Patients should be advised to take the medication at evenly spaced intervals to maintain an effective level of the drug in the body. Dosage adjustments may be necessary for patients with impaired kidney function, and any changes in the treatment regimen should be made under the supervision of a healthcare professional. As with all antibiotics, patients should be informed about the importance of adhering to the prescribed dosage and duration of treatment.

Recofast 500, classified under the anti-infectives therapeutic class, is an antibiotic medication formulated with Cefuroxime, a second-generation cephalosporin antibiotic. Each film-coated tablet of Recofast 500 contains Cefuroxime Axetil USP equivalent to 500 mg of Cefuroxime. This antibiotic is effective against a broad range of bacteria and is utilized for treating various types of bacterial infections. Cefuroxime works by disrupting the synthesis of the bacterial cell wall, leading to the eventual death of the bacteria.

Recofast 500 (Cefuroxime 500 mg) is indicated for the treatment of several bacterial infections. These infections include those of the respiratory tract, such as bronchitis and pneumonia, as well as urinary tract infections, skin and soft tissue infections, and infections of the ear, throat, and sinuses. Additionally, it is used in the treatment of Lyme disease and may be prescribed prophylactically in certain surgical procedures to prevent postoperative infections.

The dosage of Recofast 500 (Cefuroxime 500 mg) is determined based on the specific infection being treated, the severity of the condition, and patient factors such as age and renal function. For adults and children with normal kidney function, the common dosage is typically 250 mg to 500 mg taken orally twice daily. It is important for patients to take Recofast 500 with food, as this enhances the absorption of the medication. Completing the full prescribed course is crucial, even if symptoms improve, to ensure thorough eradication of the infection and to prevent the development of resistance to the antibiotic. Patients should maintain evenly spaced intervals between doses to keep a consistent level of the drug in the body. Those with impaired kidney function may require dosage adjustments, and any modifications to the treatment should be made under the supervision of a healthcare provider. Patients should be counseled on the importance of adhering to the prescribed dosage and treatment duration to achieve the best therapeutic outcome.

Recofast 750 mg, belonging to the anti-infectives therapeutic class, is an antibiotic formulated for intramuscular (IM) or intravenous (IV) administration. Each vial of Recofast 750 mg contains Cefuroxime Sodium USP equivalent to 750 mg of Cefuroxime. This antibiotic, a second-generation cephalosporin, is effective against a broad spectrum of bacteria. The medication is provided in a form that requires reconstitution, and for this, each package includes an ampoule containing 10 ml of water for injection. To ensure a safe and sterile administration, Recofast 750 mg is also supplied with a sterile disposable 10 ml syringe, an alcohol prep pad, and a strip bandage.

Recofast 750 mg (Cefuroxime 750 mg) is indicated for the treatment of various bacterial infections. This includes severe or life-threatening infections like pneumonia, urinary tract infections, skin infections, intra-abdominal infections, bone and joint infections, and meningitis. It is also used in preoperative prophylaxis for surgical infection prevention and is effective in treating infections in patients with limited treatment options due to antibiotic resistance.

The dosage of Recofast 750 mg varies depending on the type, severity, and site of infection, as well as the patient's age, weight, and kidney function. The medication is administered either intramuscularly or intravenously, depending on the clinical situation. For preparation, the Cefuroxime powder in the vial is reconstituted with the provided 10 ml of sterile water for injection. The solution should be prepared using aseptic techniques, employing the alcohol prep pad for cleaning and the sterile syringe for administration. After reconstitution, the solution should be used within a specified period to maintain efficacy and reduce the risk of contamination. Patients and healthcare providers should be instructed on the correct preparation and administration techniques. The strip bandage can be used for post-injection care. The complete course of the antibiotic should be administered as prescribed, even if symptoms improve, to ensure the effective treatment of the infection and to prevent the development of resistance. Dosage adjustments may be necessary for patients with impaired kidney function, and these should be made under the guidance of a healthcare provider.

Recofast CV 250, classified within the anti-infectives therapeutic class, is a combination antibiotic medication. Each film-coated tablet of Recofast CV 250 contains two active ingredients: 250 mg of Cefuroxime, presented as Cefuroxime Axetil USP, and 62.5 mg of Clavulanic Acid, in the form of diluted Potassium Clavulanate BP. Cefuroxime is a second-generation cephalosporin antibiotic effective against a broad spectrum of bacteria. Clavulanic Acid, on the other hand, is a beta-lactamase inhibitor that extends the antibacterial efficacy of Cefuroxime by preventing bacterial resistance to the antibiotic.

Recofast CV 250 is indicated for the treatment of various bacterial infections where the presence of beta-lactamase-producing organisms might lead to resistance against cephalosporin antibiotics like Cefuroxime alone. This includes infections of the respiratory tract, urinary tract, skin and soft tissue, and ear, throat, and sinuses. It is also used in treating more severe infections such as Lyme disease and can be prescribed in certain surgical procedures as a prophylactic measure against postoperative infections.

The dosage of Recofast CV 250 (Cefuroxime 250 mg and Clavulanic Acid 62.5 mg) is determined by the severity of the infection, the type of infecting organism, and the patient's age, weight, and renal function. For adults and children with normal kidney function, the typical dosage is one tablet taken orally twice daily. The tablets should be taken with food to enhance the absorption and efficacy of the medication. Patients are advised to complete the entire course of the antibiotic as prescribed, even if symptoms improve early, to ensure the complete eradication of the infection and to prevent the development of antibiotic resistance. Patients should maintain evenly spaced intervals between doses to keep a consistent level of the drug in the body. Dosage adjustments may be necessary for patients with impaired kidney function, and any changes in the treatment should be made under the supervision of a healthcare provider. As with all combination antibiotics, it's important for patients to understand the significance of adhering to the prescribed dosage and treatment duration.

Recofast CV 500 is an antibiotic medication falling under the anti-infectives therapeutic class. This combination drug features two active ingredients: Cefuroxime, in the form of Cefuroxime Axetil USP at a dosage of 500 mg, and Clavulanic Acid, presented as diluted Potassium Clavulanate BP at a dosage of 125 mg, per film-coated tablet. Cefuroxime is a second-generation cephalosporin antibiotic, effective against a wide range of bacteria. Clavulanic Acid acts as a beta-lactamase inhibitor, enhancing the antibacterial efficacy of Cefuroxime by preventing bacterial resistance mechanisms.

Recofast CV 500 is indicated for the treatment of a variety of bacterial infections, particularly where beta-lactamase-producing bacteria might render cephalosporins like Cefuroxime less effective. This includes infections of the respiratory tract, urinary tract, skin and soft tissues, and those affecting the ear, throat, and sinuses. It is also suitable for treating more complex infections such as Lyme disease and can be used as a prophylactic measure in certain surgical procedures to prevent postoperative infections.

The dosage of Recofast CV 500 (Cefuroxime 500 mg and Clavulanic Acid 125 mg) is based on the nature and severity of the infection, as well as the patient's age, body weight, and kidney function. In adults and children with normal kidney function, the usual dosage is one tablet taken orally twice daily. Patients are advised to take the tablets with food, as this can improve the absorption and effectiveness of the medication. Completing the full prescribed course is essential, even if symptoms improve before the medication is finished, to ensure thorough eradication of the infection and to prevent the development of antibiotic resistance. It is important to maintain evenly spaced intervals between doses to ensure a consistent level of the drug in the body. Patients with impaired kidney function may require dosage adjustments, and these should be made under the guidance of a healthcare provider. Adherence to the prescribed dosage and duration of treatment is crucial for the success of the therapy.

Recofast GS is an antibiotic medication classified under the anti-infectives therapeutic class. It is formulated as a powder for oral suspension, specifically designed for pediatric use. Each 5 ml of the prepared suspension contains 125 mg of Cefuroxime. Cefuroxime is a second-generation cephalosporin antibiotic effective against a broad spectrum of bacteria. The medication is presented in a 70 ml bottle when reconstituted and is flavored with a mix of banana and vanilla to make it more palatable for children.

Recofast GS (Cefuroxime 125 mg per 5 ml) is indicated for the treatment of various bacterial infections in children. These infections can include those of the respiratory tract (such as bronchitis and pneumonia), ear (like otitis media), skin and soft tissue infections, and urinary tract infections. It is also used for treating conditions like Lyme disease in children and can be prescribed for bacterial infections where the causative organism is susceptible to Cefuroxime.

The dosage of Recofast GS is determined based on the child's weight, age, and the severity of the infection. The typical pediatric dosage usually involves administering the medication in a dose calculated as per the child's body weight, with a common regimen being 10-15 mg/kg of body weight, given twice daily. The exact dosage and duration of treatment should be prescribed by a healthcare provider. To prepare the suspension, the powder should be reconstituted with water as per the manufacturer's instructions, ensuring that the final volume is 70 ml. Before each use, the bottle should be well shaken to ensure that the medication is evenly mixed. It's important for the full course of the antibiotic to be completed as prescribed to fully eradicate the infection and prevent the development of antibiotic resistance. Parents and caregivers should be guided on the correct preparation, dosage measurement, and administration of the suspension. Any unused suspension should typically be discarded after a certain number of days as advised by the manufacturer or healthcare provider. Dosage adjustments or treatment changes should be made under the guidance of a healthcare professional.

Fighting bacterial infections involves the use of antibiotics, which are medications designed to target and eliminate bacteria. The choice of antibiotic depends on the type of bacteria causing the infection. It's crucial to complete the full course of prescribed antibiotics, even if symptoms improve, to prevent antibiotic resistance.

Fighting Bacterial Infections

We believe
any illness
has remedy.